Current Report Filing (8-k)
February 07 2023 - 4:07PM
Edgar (US Regulatory)
NASDAQ NASDAQ NASDAQ 00000 false 0001839185 0001839185 2023-02-03 2023-02-03 0001839185 us-gaap:CapitalUnitsMember 2023-02-03 2023-02-03 0001839185 us-gaap:CommonClassAMember 2023-02-03 2023-02-03 0001839185 us-gaap:WarrantMember 2023-02-03 2023-02-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2023
SUMMIT HEALTHCARE ACQUISITION CORP.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Cayman Islands |
|
001-40466 |
|
98-1574360 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
Unit 1101, 11th Floor 1 Lyndhurst Tower, 1 Lyndhurst Terrace Central, Hong Kong |
|
N/A |
(Address of Principal Executive Offices) |
|
(Zip Code) |
+852-2155-7212
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant |
|
SMIHU |
|
Nasdaq Capital Market |
Class A ordinary shares, par value $0.0001 per share, included as part of the units |
|
SMIH |
|
Nasdaq Capital Market |
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 |
|
SMIHW |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On February 3, 2023, Summit Healthcare Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq Capital Market.
The Notice states that the Company has 45 calendar days to submit a plan to regain compliance with the Minimum Public Holders Rule. The Company intends to submit a plan to regain compliance with the Minimum Public Holders Rule within the required timeframe. If Nasdaq accepts Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with the Minimum Public Holders Rule. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUMMIT HEALTHCARE ACQUISITION CORP. |
Dated: February 7, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Bo Tan |
|
|
|
|
|
|
Bo Tan |
|
|
|
|
|
|
Chief Executive Officer, Co-Chief Investment Officer and Director |
Summit Healthcare Acquis... (NASDAQ:SMIH)
Historical Stock Chart
From Dec 2024 to Jan 2025
Summit Healthcare Acquis... (NASDAQ:SMIH)
Historical Stock Chart
From Jan 2024 to Jan 2025